Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
Pharmacol Ther
; 226: 107878, 2021 10.
Article
en En
| MEDLINE
| ID: mdl-33895189
ABSTRACT
Recent years have seen a renewed interest on the possible therapeutic exploitations of specific cannabinoids derived from the Cannabis sativa plant. Thus far, the most studied non-psychotomimetic cannabinoid is cannabidiol (CBD), which has shown promising therapeutic potential for relieving a variety of neurological diseases. However, also its propyl analogue, cannabidivarin (CBDV), has recently gained much attention as a potential therapeutic agent for the management of disabling neurological conditions. This review aims at providing a comprehensive and updated overview of the available animal and human data, which have investigated the possible therapeutic potential of CBDV for the management of epilepsy and autism spectrum disorder.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Cannabinoides
/
Epilepsia
/
Trastorno del Espectro Autista
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Pharmacol Ther
Año:
2021
Tipo del documento:
Article